t has been recognized since the early days of catheter ablation to treat atrial fibrillation (AF) that some patients can have early recurrences of AF in the weeks after ablation. This has been attributed to the effects of inflammation and pericarditis after ablation; several studies have shown that antiinflammatory agents such as colchicine (1) may reduce these early recurrences. In paroxysmal AF patients, early recurrences clearly increase the risk of late recurrences, while in patients with persistent AF, such an association is less certain.
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Early AF after ablation can be a source of frustration for patients, as they have just gone through an extensive procedure to treat their AF, only to suffer recurrent bothersome episodes. Such recurrences can also increase the burden and cost to providers, as patients require additional medication adjustments, cardioversions, and sometimes hospital admission.
The cost to the healthcare system after an expensive ablation procedure should not be underestimated. Certainly for bothersome recurrent AF symptoms, the manuscript would support initiation of amiodarone,
Antiarrhythmics After AF Ablation One would need a more detailed prospective study measuring quality of life and cost to conclusively determine whether an empiric strategy of amiodarone for 3 months after ablation was worthwhile.
However, the authors data has taught us that in some patients at risk for early AF recurrence, empiric AAD therapy for several months after ablation is reasonable and may reduce hospitalizations.
Meanwhile, the quest to reduce early AF recurrences after ablation will continue.
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